John Sharp
2018
In 2018, John Sharp earned a total compensation of $465.4K as Chief Financial Officer at PhaseBio Pharmaceuticals, a 26% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $131,900 |
|---|---|
| Option Awards | $13,813 |
| Salary | $319,027 |
| Other | $690 |
| Total | $465,430 |
Sharp received $319K in salary, accounting for 69% of the total pay in 2018.
Sharp also received $131.9K in non-equity incentive plan, $13.8K in option awards and $690 in other compensation.
Rankings
In 2018, John Sharp's compensation ranked 12,108th out of 14,244 executives tracked by ExecPay. In other words, Sharp earned more than 15.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,108 out of 14,244 | 15th |
Division Manufacturing | 4,901 out of 5,759 | 15th |
Major group Chemicals And Allied Products | 1,849 out of 2,122 | 13th |
Industry group Drugs | 1,578 out of 1,811 | 13th |
Industry Pharmaceutical Preparations | 1,209 out of 1,385 | 13th |
Source: SEC filing on April 5, 2019.
Sharp's colleagues
We found three more compensation records of executives who worked with John Sharp at PhaseBio Pharmaceuticals in 2018.